Brief: Nicox H1 Net Loss Narrows To 6.6 Million Euros

Nicox SA

20/10/2023 06:46

Oct 20 (Reuters) - Nicox SA  ALCOX.PA :
    * THIRD QUARTER 2023 U.S. PRESCRIPTIONS FOR VYZULTA
INCREASED BY
22% OVER THIRD QUARTER 2022
    * NET REVENUE €1.7 MILLION FOR FIRST HALF 2023 AND €1.1
MILLION
FOR THIRD QUARTER 2023
    * CASH OF €14.6 MILLION ON SEPTEMBER 30, 2023
    * NCX 470 PHASE 3 DENALI CLINICAL TRIAL OVER 65% RANDOMIZED
    * OPERATING EXPENSES FOR FIRST HALF OF 2023 WERE EUR 10.4
MILLION
COMPARED TO EUR 12.7 MILLION FOR FIRST HALF OF 2022
    * RECORDED A NET LOSS OF €6.6 MILLION FOR THE SIX MONTHS
ENDED
JUNE 30, 2023, COMPARED TO A NET LOSS OF €17.0 MILLION FOR THE
SAME PERIOD IN 2022

Source text for Eikon:  ID:nGNEbm6j4C 
Further company coverage:  ALCOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))